# GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide
Canonical URL: https://biopharmsignal.com/news/GDRX/goodrx-expands-access-to-eli-lilly-and-company-s-new-oral-glp-1-foundayotm-and-zepboundr-kwikpenr-with-self-pay-pricing-at-more-than-70-000-pharmacies-nationwide
Ticker: GDRX
Company: GoodRx
Source: GoodRx
Published: 2026-04-09 11:30 EST
Original Source URL: https://investors.goodrx.com
## Summary

Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx Brief Summary: GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron) Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx

## Article Body
Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx Brief Summary: GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron) Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx
## Recent Company News
- 2026-05-27 13:00 EST — [GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs](https://biopharmsignal.com/news/GDRX/goodrx-launches-goodrx-companion-a-new-subscription-designed-to-lower-everyday-healthcare-costs) — Source: GoodRx
- 2026-05-06 20:05 EST — [GoodRx Reports First Quarter 2026 Results](https://biopharmsignal.com/news/GDRX/goodrx-reports-first-quarter-2026-results) — Source: GoodRx
- 2026-05-01 12:10 EST — [GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients](https://biopharmsignal.com/news/GDRX/goodrx-expands-offerings-to-now-include-ozempicr-pill-for-type-2-diabetes-patients) — Source: GoodRx
- 2026-04-17 20:05 EST — [GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/GDRX/goodrx-announces-date-for-first-quarter-2026-earnings-release-and-conference-call) — Source: GoodRx
- 2026-04-15 13:00 EST — [GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price](https://biopharmsignal.com/news/GDRX/goodrx-now-offers-access-to-wegovyr-hd-at-399-per-month-self-pay-price) — Source: GoodRx
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)